drugset / Trial / NCT07081932
A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood
NaSequentialOpen-labelTreatment
Summary
The main objective of this trial is to investigate the effect of bosentan, a moderate Cytochrome P450 (CYP) 3A inducer on the single dose pharmacokinetics of nerandomilast.
Timeline
- Start
- 2025-08-26
- Primary completion
- 2025-09-27
- Completion
- 2025-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosentan | Other / unclassified | — | — |
| Subject | Nerandomilast | Small molecule | — | — |
Indications
No indication recorded.